Shanghai-based NeuroXess, which is developing BCI technology for movement support, speech decoding, and control of external devices, raised a ~$105M Series B

The cost of advanced BCI implants drops significantly, making formerly inaccessible medical technologies viable for a broader patient population.

Shanghai-based NeuroXess, a company developing brain-computer interface (BCI) technology, has secured approximately $105 million (RMB 700 million) in Series B funding. The round was co-led by SDIC Juli, Shenzhen Capital Group, and Qinzhi Capital. NeuroXess plans to use the capital for multicenter clinical trials, regulatory submissions, scaling manufacturing capacity, and advancing its next-generation products. The company's implantable BCI systems combine flexible electrodes with wireless power and data transmission, aiming to assist with movement, decode speech, and control external devices. NeuroXess has completed 65 clinical cases and initiated a registration trial involving nearly 20 hospitals. It is also constructing a 14,300-square-meter manufacturing facility with a projected annual capacity of 10,000 systems.

This substantial funding round underscores significant investor confidence in the burgeoning BCI market, particularly for implantable solutions. NeuroXess's ability to attract major capital suggests a maturing technological pathway toward clinical viability and commercialization for complex neuroprosthetics. The company's focus on both movement and speech decoding indicates a broad therapeutic scope, positioning it to address a wide range of neurological conditions.

The expansion of manufacturing capacity signals a move from research and development to scalable production, a critical step for widespread adoption. This increased output could lead to greater competition and potentially drive down costs for BCI systems. Investors will be watching NeuroXess's regulatory progress closely, as successful submissions are key to unlocking market access and demonstrating the therapeutic and assistive potential of their technology.